martedì, 5 maggio 2026

Notizie AIOM – anno XV

FDA Grants 510(k) Clearance to Halcyon IMRT Treatment System

July 7, 2017 - Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Halcyon system, a new device for cancer treatment. Halcyon simplifies and enhances image-guided volumetric-intensity modulated radiotherapy (IMRT). “We ...
Leggi tutto

7 luglio 2017 – Comunicazione EMA su gadolinio

7 luglio 2017 – Comunicazione EMA su metilprednisolone

Corticosteroids for the management of nausea and vomiting not related to chemotherapy, radiotherapy, or surgery in adult cancer patients

Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%. While nausea and vomiting can be related to cancer treatments, such as chemotherapy, radiotherapy, or surgery, a significant number of people with advanced cancer also suffer from nausea unrelated ...
Leggi tutto

FDA Grants Marketing Approval to the Praxis Extended RAS Panel

July 6, 2017 - On June 29, the U.S. Food and Drug Administration (FDA) granted marketing approval to the Praxis Extended RAS Panel, a next-generation sequencing test to detect certain genetic mutations in RAS genes in tumor samples of patients with metastatic colorectal ...
Leggi tutto

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6, 2017 - The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab trials and ordered the discontinuation of the lenalidomide/ dexamethasone/ pembrolizumab arm of the KEYNOTE-023 trial. All 3 studies were evaluating the PD-1 inhibitor ...
Leggi tutto

Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer

While there is an increasing trend of ovarian conservation at the time of surgical treatment for young women with stage I cervical cancer, the risk for subsequent ovarian cancer after ovarian conservation has not been well studied. To examine the incidence of and risk factors ...
Leggi tutto

È online la versione italiana dei PRO-CTCAE: un grande servizio per i malati e per l’oncologia medica del nostro Paese

È disponibile, sul sito web del National Cancer Institute, la versione italiana dei PRO-CTCAE (Patient Reported Outcomes - Common Terminology Criteria for Adverse Event). Si tratta di un questionario utilizzato nelle ricerche cliniche negli USA e in altri Paesi: consente ...
Leggi tutto

Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research

In the modern era of patient-centered drug development, the only way to translate biological and genomic discoveries into clinically meaningful therapies is through partnerships among academia, industry, and government. To ensure that the integrity of the research is beyond ...
Leggi tutto

Premio ai 4 migliori progetti di ricerca in artrite psoriasica, psoriasi, mieloma multiplo e carcinoma del pancreas

Il concorso è destinato a medici o biologi di età inferiore o uguale a 40 anni Realizzato in collaborazione con le Società Scientifiche AIOM, SIDeMaST, SIE e SIR Scadenza presentazione progetti: 15 settembre 2017